Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer

The phase III ALASCCA trial presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Dr. Anna Martling demonstrates a 51% reduced risk of colorectal cancer recurrence with adjuvant daily aspirin in patients harboring PI3K pathway alterations. It's the first study to show that somatic alterations in the PI3K signaling pathway predict aspirin response, expanding the targetable patient population.